The number of patients prescribed TAKHZYRO since 2018 is based on third-party US specialty pharmacy data.

WHAT IS TAKHZYRO?

TAKHZYRO is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 2 years of age and older.

It is not known if TAKHZYRO is safe and effective in children under 2 years of age.

IMPORTANT SAFETY INFORMATION

TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms:

- wheezing
- difficulty breathing
- chest tightness
- fast heartbeat
- faintness
- rash
- hives

Please see additional Important Safety Information throughout and full Prescribing Information, including information for patients.

TAKHZYRO®
(lanadelumab-flyo) injection 300 mg·150 mg

Individuals featured are TAKHZYRO patients as of 2024 and are sharing their own experiences. Individual experiences may vary.

IMPORTANT SAFETY INFORMATION (cont'd)

The most common side effects seen with TAKHZYRO were injection site reactions (pain, redness, and bruising), upper respiratory infection, headache, rash, dizziness, diarrhea, and muscle aches.

These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist. You may report side effects to FDA at 1-800-FDA-1088.

EFFECTIVE PREVENTION AS SEEN IN A 6.5-MONTH STUDY

You and your doctor likely chose to manage your hereditary angioedema (HAE) with TAKHZYRO for several reasons. One of those may have had to do with the results of the clinical studies. In those studies, people taking TAKHZYRO had fewer HAE attacks on average, and some even had periods of zero attacks.

Some details about the first study

The study lasted 6.5 months and included 125 people with HAE aged 12 years and older.

- The goal was to evaluate the efficacy and safety of TAKHZYRO
- People taking TAKHZYRO 300 mg every 2 weeks **saw a significant reduction in the number of monthly attacks by 87%** (average monthly attack rate of 0.3 vs 2.0) on average compared with placebo
- They also had an average of **83% fewer moderate or severe attacks** and **87% fewer attacks requiring on-demand treatment** compared with placebo
- **44%** of people taking TAKHZYRO 300 mg every 2 weeks had **zero attacks during the entire clinical study** compared with 2% taking placebo

TAKHZYRO was also looked at in a long-term, open-label extension study

This study lasted 2.5 years and included 212 people with HAE aged 12 years and older. It looked at the long-term safety and efficacy of TAKHZYRO. Patients knew they were receiving TAKHZYRO, which could have influenced the results. **The study showed similar and consistent results to the first study. For safety results, see page 12.**

Please see additional Important Safety Information throughout and full Prescribing Information, including information for patients.

TAKHZYRO®
(lanadelumab-flyo) injection 300 mg·150 mg

SUPPORT FOR YOUR JOURNEY BACKED BY TAKEDA'S 15+ YEARS OF EXPERIENCE

What you can expect when getting your TAKHZYRO

All HAE medications are provided by specialty pharmacies. Insurance companies often require additional information to approve this type of prescription medication. Sometimes it can take a month to coordinate the delivery of your first shipment of TAKHZYRO. **This is normal.**

The good news is, we provide support at no cost to you. And we will work to make sure you get your TAKHZYRO as quickly as possible.

Questions about TAKHZYRO?

You can get answers to FAQs by visiting **TAKHZYRO.com**. Remember to talk to your doctor about any questions you may have.

We've been there for people with HAE since 2008

- TAKHZYRO is the #1 prescribed HAE preventive treatment*
- Takeda has been supporting people with HAE since 2008
- Takeda Patient Support has been providing product support services for 12 years
- TAKHZYRO has been evaluated in one of the largest prevention studies in HAE and has been prescribed to over 4,000 people since it was approved in 2018†

"My doctor wanted me to try TAKHZYRO, and I trusted their medical recommendation. TAKHZYRO has definitely made a big difference for me. I'm glad I listened!"

— Dennis

His TAKHZYRO experience started in 2018

IMPORTANT SAFETY INFORMATION (cont'd)

TAKHZYRO has not been studied in pregnant or breastfeeding women. Talk to your healthcare provider about the risk of taking TAKHZYRO if you are pregnant, plan to be pregnant, are breastfeeding, or plan to breastfeed.

*Based on total patients on HAE preventive treatments according to US third-party industry healthcare data.

†Based on third-party US specialty pharmacy data.

Please see additional Important Safety Information throughout and full Prescribing Information, including information for patients.

TAKHZYRO® (lanadelumab-flyo) injection 300 mg·150 mg

START OFF RIGHT WITH TREATMENT GOALS

You and your doctor decided effective prevention with TAKHZYRO could help reduce the frequency and severity of your HAE attacks. As part of your HAE management plan, treatment with TAKHZYRO could also help you achieve your treatment goals.

What do you hope to achieve with TAKHZYRO?

Start by thinking about your experience with HAE today. This will give you a snapshot of your "before TAKHZYRO." After taking TAKHZYRO for a few months, you can see how the frequency and severity of your HAE attacks may have changed. Write down the answers to these questions:

- How often are my attacks now?
- How severe are they?
- How often do I use my on-demand medication?

Watch Bob's video to hear him talk about setting goals for his HAE management plan.

IMPORTANT SAFETY INFORMATION

TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms:

- wheezing
- difficulty breathing
- chest tightness
- fast heartbeat
- faintness
- rash
- hives

Please see additional Important Safety Information throughout and full Prescribing Information, including information for patients.

TAKHZYRO®
(lanadelumab-flyo) injection 300 mg·150 mg

"I continue to take TAKHZYRO as prescribed by my doctor. It's helped decrease my attack frequency and severity."

— Jenny
Her TAKHZYRO experience started in 2018

GIVE TAKHZYRO 2.5 MONTHS TO REACH STEADY STATE

What do we mean by "steady state"?

With your first dose of TAKHZYRO, the medicine will start to build up in your body. **Over the course of your first 6 doses, TAKHZYRO will reach a constant level—also known as "steady state."** Once you get there, it's important to keep taking TAKHZYRO exactly as prescribed to help maintain steady state.



IMPORTANT SAFETY INFORMATION (cont'd)

The most common side effects seen with TAKHZYRO were injection site reactions (pain, redness, and bruising), upper respiratory infection, headache, rash, dizziness, diarrhea, and muscle aches.

These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist. You may report side effects to FDA at 1-800-FDA-1088.

Please see additional Important Safety Information throughout and full Prescribing Information, including information for patients.

TAKHZYRO®
(lanadelumab-flyo) injection 300 mg·150 mg

MAKE A COMMITMENT TO YOURSELF AND TAKHZYRO

Take each dose as prescribed

TAKHZYRO continues to work as you take it, so it is important to take each dose as prescribed by your doctor. **Remember also to avoid missing or skipping doses.**

Breakthrough attacks

It's possible to experience breakthrough attacks while taking TAKHZYRO. Some people may experience them more frequently in the first few months of treatment.

It is recommended to keep your on-demand medication on hand in case of a breakthrough attack.

If a breakthrough attack happens, don't be discouraged. Keep taking TAKHZYRO as prescribed, and talk with your doctor about your experience.

Stay the course

Over time, you may begin to notice your attacks are less severe or that you are using your on-demand treatment less. **These are signs that TAKHZYRO is working.**

In a later analysis of the 6.5-month clinical study:



After patients received their sixth dose of TAKHZYRO, **77% had ZERO attacks for the last 4 months of the study**. Compared to 3% of those taking placebo.

- In the same study, **44% of people had zero attacks for the entire 6.5 months** compared with 2% of people taking placebo
- While supportive of the main findings, the results above were not the primary focus of the clinical study. It was not designed to measure the percentage of people who had zero attacks after 2.5 months of treatment through the end of the study

Get dosing reminders!

You can get text message reminders to help you stay on track with TAKHZYRO. **Click here** or text SIGNUP (o RECORDAR en español) to 36395.

IMPORTANT SAFETY INFORMATION (cont'd)

TAKHZYRO has not been studied in pregnant or breastfeeding women. Talk to your healthcare provider about the risk of taking TAKHZYRO if you are pregnant, plan to be pregnant, are breastfeeding, or plan to breastfeed.

Please see additional Important Safety Information throughout and full Prescribing Information, including information for patients.

TAKHZYRO®
(lanadelumab-flyo) injection 300 mg·150 mg

SAFETY RESULTS ESTABLISHED IN ONE OF THE LARGEST PREVENTION STUDIES IN HAE

TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have symptoms of an allergic reaction.

The most common side effects seen in both clinical studies included:

- **Injection site reactions.** These are the most common side effects of TAKHZYRO. People who received TAKHZYRO in the clinical studies reported pain, redness, or bruising in the area where TAKHZYRO was injected. These reactions are expected
  - Be sure to follow the administration technique as demonstrated in the Instructions for Use
  - Remember, you will be taught how to properly inject TAKHZYRO by a specially trained nurse before your first dose. **Do not attempt to take TAKHZYRO without first being trained by a healthcare provider**
- **Upper respiratory infections.** Common examples are when someone gets a cold or the flu
- **Headaches**

Just as everyone's experience with HAE is different, every person will respond to medication differently. It is important to share any side effects you may experience with your healthcare provider. They can help you manage them.

You may report side effects to FDA at 1-800-FDA-1088.

IMPORTANT SAFETY INFORMATION

TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms:

- wheezing
- chest tightness
- faintness
- hives
- difficulty breathing
- fast heartbeat
- rash

Most common side effects in the 6.5-month clinical study	TAKHZYRO (84 people)*	Placebo (41 people)
Injection site reactions	52%	34%
○ Pain	43%	29%
○ Redness	10%	2%
○ Bruising	7%	0%
Upper respiratory infection	29%	32%
Headache	21%	22%
Rash	7%	5%
Dizziness	6%	0%
Diarrhea	5%	5%
Muscle aches	5%	0%

Safety data from the 2.5-year open-label extension study were consistent with the safety data from the 6.5-month study.

All side effects above occurred in ≥10% of people taking TAKHZYRO.

*Includes all people treated with TAKHZYRO (300 mg every 2 weeks, 300 mg every 4 weeks, or 150 mg every 4 weeks) in the first study.

Please see additional Important Safety Information throughout and full Prescribing Information, including information for patients.

TAKHZYRO®
(lanadelumab-flyo) injection 300 mg·150 mg

Takeda Patient Support

Your Source for Education and Access

Supporting patients with HAE for over 16 years

At Takeda Patient Support, we provide you with tailored support for your therapy

Takeda Patient Support offers tailored support for TAKHZYRO® (lanadelumab-flyo). We understand that living with HAE looks different for everyone. Our long-term commitment to the HAE community allows us to better understand and meet your needs.

Our support specialists are here to address your questions and help get you the resources you need. Some of the resources we offer include:

- **Enrolling** you in the **Takeda Patient Support Co-Pay Assistance Program**, if you qualify*
- **Working** with your specialty pharmacy to **help you receive TAKHZYRO**
- **Arranging** for **in-home injection training** from a specially trained nurse
- **Navigating** the **health insurance** process, along with help accessing financial insurance. Eligible patients can have their co-pays covered at 100%, up to the program maximum*
- **Directing** you to **community support resources and education**

*To be eligible, you must be enrolled in Takeda Patient Support and have commercial insurance. Other terms and conditions apply. Call Takeda Patient Support for more details.

“Takeda Patient Support was there for me right when I started TAKHZYRO. And Lisa, my PSM, still calls me to make sure I’m doing OK and getting my treatment on time.”

— **Soraya**
Her TAKHZYRO experience started in 2018

Have questions? Call Takeda Patient Support at **1-866-888-0660**, Monday through Friday, 8:30 AM to 8:00 PM ET.

If English is not your preferred language, we can communicate with you over the phone using a translation service.

Please see additional Important Safety Information throughout and full Prescribing Information, including information for patients.

THE *#1 PRESCRIBED* HAE PREVENTIVE TREATMENT*

- **Clinical results:** In the 6.5-month study, people 12 years of age and older taking TAKHZYRO saw a reduction in the number of monthly attacks by 87% on average compared with placebo
- **Experience:** TAKHZYRO has been prescribed to over 4,000 people since 2018, based on third-party US specialty pharmacy data
- **Support:** Takeda Patient Support has been helping to ensure people have access to their treatment and the tools they need for 12 years

*Based on total patients on HAE preventive treatments according to US third-party industry healthcare data.

WHAT IS TAKHZYRO?

TAKHZYRO is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 2 years of age and older.

It is not known if TAKHZYRO is safe and effective in children under 2 years of age.

IMPORTANT SAFETY INFORMATION

TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms:

- wheezing
- difficulty breathing
- chest tightness
- fast heartbeat
- faintness
- rash
- hives

Please see additional Important Safety Information throughout and full Prescribing Information, including information for patients.

Takeda

©2024 Takeda Pharmaceuticals U.S.A., Inc., 500 Kendall Street, Cambridge, MA 02142. 1-877-TAKEDA-7 (1-877-825-3327). All rights reserved. TAKEDA®, the TAKEDA Logo®, and the TAKEDA Patient Support Logo™ are trademarks or registered trademarks of Takeda Pharmaceutical Company Limited. TAKHZYRO® is a registered trademark of Dyax Corp.
US-LANA-1581v2.0 08/24

Visit us on:

TAKHZYRO®
(lanadelumab-flyo) injection 300 mg·150 mg